Rezdiffra's $364M Quarter Validates MASH Market, But Incretin Showdown Looms Without Head-to-Head Data

Madrigal Reports Strong Q2 2026 Rezdiffra Sales and Pipeline Progress

Madrigal Pharmaceuticals announced strong second-quarter 2026 financial results, with Rezdiffra® (resmetirom) net sales reaching $364.3 million, marking a 71% year-over-year increase. The company reported over 49,000 patients on Rezdiffra as of June 30, 2026, more than doubling from Q2 2025, and surpassed 50,000 active patients in July. Madrigal also strengthened Rezdiffra's intellectual property with three new patents extending protection into 2042-2045 and initiated a Phase 1 trial for MGL-2086, an oral GLP-1, as part of a combination program with Rezdiffra for MASH. The company concluded the quarter with $838.9 million in cash, cash equivalents, restricted cash, and marketable securities.

• Madrigal Pharmaceuticals demonstrated robust commercial performance for Rezdiffra, achieving $364.3 million in net sales for the second quarter of 2026, representing a significant 71% increase compared to the prior year. This growth was supported by strong physician adoption and high patient demand, leading to over 49,000 patients on Rezdiffra by June 30, 2026, and surpassing 50,000 active patients earlier in July, highlighting its position as a foundational MASH medicine.
• The company significantly strengthened Rezdiffra's intellectual property portfolio with the issuance of three new U.S. patents. These patents cover specific dosing regimens for F2-F3 MASH patients using CYP2C8 inhibitors (extending protection into 2045), co-administration with rosuvastatin (protection into 2042), and methods for treating well-compensated cirrhosis (F4c) (protection into 2042), reinforcing long-term market exclusivity.
• Madrigal advanced its pipeline by initiating a Phase 1 single ascending dose (SAD) trial for MGL-2086, an oral GLP-1 receptor agonist, in healthy volunteers. This move is a key step in Madrigal's strategy to develop innovative combination treatments for MASH, anchored by Rezdiffra, with the goal of creating a best-in-disease, once-daily oral therapy that leverages the potential for enhanced antifibrotic efficacy through modest weight loss.
• Recent data presentations at the EASL Congress reinforced Rezdiffra's efficacy, including real-world data showing nearly 50% of patients achieved at least a 25% improvement in liver stiffness over approximately nine months. Secondary analyses from Phase 3 trials also demonstrated Rezdiffra's ability to improve MASH endpoints and significantly reduce atherogenic lipoproteins, supporting its potential to address both liver disease and cardiometabolic risk. Madrigal also launched the 'MASH Across America' initiative to expand disease awareness.

Rezdiffra's Expanding Evidence: Liver Stiffness, F4c, and CV Benefits

Recent clinical investigations highlight the promise of incretin-based therapies for MASH. In the 52-week SYNERGY-NASH trial, the dual GIP/GLP-1 receptor agonist tirzepatide demonstrated high rates of MASH resolution without worsening fibrosis and achieved meaningful fibrosis regression. It also conferred substantial weight loss, improved glycemic control, and reduced hepatic biomarkers including ALT, AST, K-18, and Pro-C3. Similarly, the SYNCHRONIZE-MASLD Phase 3 trial of survodutide, a dual glucagon/GLP-1 receptor agonist, met its co-primary endpoints at 48 weeks, with 84.2% of participants achieving a ≥30% reduction in liver fat content versus 24.3% for placebo (P<0.0001). A 2026 meta-analysis of GLP-1 receptor agonists further solidified the class effect, showing a significant odds ratio for MASH resolution (OR 4.16, p<0.001) and fibrosis regression (OR 2.02, p=0.01) at 18 months, with a pooled serious adverse event rate comparable to placebo.

Beyond incretins, other mechanisms of action are also showing significant efficacy. A 2025 systematic review of four Phase 2 trials on the FGF21 analogue efruxifermin found it superior to placebo in reducing hepatic fat fraction, the enhanced liver fibrosis (ELF) score, Pro-C3, and liver stiffness. Efruxifermin also demonstrated superiority in achieving MASH resolution and fibrosis regression. However, efficacy was accompanied by dose-dependent gastrointestinal side effects, with the 50 mg dose showing higher risks of TEAEs leading to discontinuation (RR=3.05), nausea (RR=1.78), and diarrhea (RR=1.9). In a different mechanistic class, the PPAR pan-agonist chiglitazar showed a significant, dose-dependent reduction in liver fat content in a Phase II study. At 18 weeks, the 64 mg dose achieved a -39.5% change from baseline versus -3.2% for placebo (difference vs. placebo -36.3%, p<0.001), with a favorable safety profile of mostly mild to moderate adverse events.

MGL-2086: Advancing Combination Therapy for MASH with Rezdiffra

Combination therapy for MASH has been most rigorously evaluated in the MAESTRO-NASH trial, a randomised, double-blind, placebo-controlled, 54-month phase 3 study assessing resmetirom—a liver-directed, selective thyroid hormone receptor beta agonist that received FDA accelerated approval in March 2024 for noncirrhotic MASH with F2-F3 fibrosis—alongside background GLP-1 receptor agonist (GLP-1 RA) or SGLT2 inhibitor (SGLT2i) therapy. At baseline, 13%-17% of enrolled patients (all with type 2 diabetes mellitus) were on stable GLP-1 RA or SGLT2i regimens in addition to resmetirom. Notably, resmetirom's efficacy across multiple MASH endpoints was not diminished by this background therapy, with patients on SGLT2i or GLP-1 RA achieving comparable rates of MASH resolution and fibrosis improvement to those not receiving these agents. However, no additional weight loss beyond baseline was observed when GLP-1 RA or SGLT2i was added to resmetirom. Weight loss itself emerged as a key modifier of treatment response: resmetirom-treated patients (100 mg) achieving ≥5% weight loss demonstrated markedly higher rates of MASH resolution (56.6% vs. 33.8%), fibrosis improvement (40.6% vs. 31.5%), MRI-PDFF reduction (-69% vs. -46%), and liver stiffness reduction (-4.6 kPa vs. -2.3 kPa) at 52 weeks compared with those losing less weight—underscoring weight loss as a cornerstone of MASLD management and a potential amplifier of resmetirom's hepatic effects.

Beyond resmetirom-based regimens, incretin-based therapies are independently advancing as both monotherapy and combination candidates. Semaglutide 2.4 mg/week, approved for MASH treatment in 2024, has demonstrated superior efficacy in achieving MASH resolution (pooled odds ratio 3.48, 95% CI 2.69-4.51) and improving fibrosis (pooled odds ratio 1.79, 95% CI 1.37-2.35) over 72 weeks, alongside significant reductions in MR-measured liver fat content (pooled mean difference: -4.50%, 95% CI -6.60 to -2.40%). Emerging dual and triple receptor agonists—incorporating glucose-dependent insulinotropic peptide and/or glucagon receptor agonism—have shown considerable improvements in liver fat content and histology in phase 2 studies, positioning multi-agonist incretin therapies as promising future combination partners. In parallel, FGF-21 analogues represent another mechanistically distinct class under active investigation: efimosfermin, a long-acting once-monthly agent, has shown beneficial effects on MASH resolution and fibrosis regression in patients with F2/F3 fibrosis, while other agents in this class (efruxifermin, pegozafermin, pegbelfermin, BOS-580) have produced significant phase 2 improvements in liver fat, fibrosis, and liver function through pleiotropic effects on both hepatic and systemic metabolism.

Mechanistically, a proposed AMPK-centric framework offers a unifying rationale for combination strategy design, positioning AMP-activated protein kinase as the master regulator of hepatic energy homeostasis onto which pioglitazone, GLP-1 RAs, SGLT2is, resmetirom, and statins all converge—either indirectly via systemic effects such as weight loss and glycemic control, or directly through hepatocyte-specific actions. This framework explicitly contrasts the liver-targeted mechanism of resmetirom with the predominantly systemic effects of semaglutide, offering a rationale for complementary rather than redundant combination approaches. Despite this mechanistic appeal, current consensus recommendations (2026) support consideration of resmetirom or semaglutide monotherapy for noncirrhotic MASLD patients with liver stiffness measurements of 10-20 kPa or ELF values of 9.2-11.3, but explicitly do not recommend upfront combination therapy with both agents. Instead, pharmacologic selection should be individualized through shared decision-making based on the patient's cardiometabolic profile, with treatment response at one year defined as ≥30% reduction in liver stiffness or ≥0.5-point reduction in ELF. Given this evolving landscape, a multidisciplinary approach involving both diabetologists and hepatologists is considered optimal for guiding MASLD/MASH management.

Addressing Unmet Needs in MASH: A Rapidly Evolving Landscape

The MASH treatment landscape has shifted markedly over the past three years, moving from a field with virtually no approved therapies to one experiencing its first regulatory breakthroughs. Despite this progress, significant gaps remain in biomarker validation, patient stratification, and long-term disease management, while specific high-risk populations are increasingly being defined for targeted intervention.

• High-risk target population: Obese patients with MASH ≤F3 fibrosis without diabetes represent a key subgroup at elevated risk of progressing to advanced liver disease; in Italy alone, this population is estimated at 782,920 obese adults, underscoring the scale of unmet need even within a single market.

• Persistent clinical development challenges: The field continues to face the absence of dynamic, validated biomarkers of treatment response, continued reliance on biopsy-based surrogate endpoints, high placebo response rates in trials, and substantial heterogeneity in disease biology and clinical trajectory — all of which complicate trial design and patient selection.

• Transformative regulatory milestones: After decades of limited therapeutic options, the FDA's conditional approvals of resmetirom and semaglutide mark a pivotal shift in MASH management, validating strategies that target both upstream metabolic dysfunction and intrahepatic injury. Numerous additional candidates are now advancing rapidly through late-stage development, with growing interest in rational combination approaches tailored to patient phenotype and disease stage.

• Emerging diagnostic and monitoring tools: Noninvasive tests and multi-omic profiling are poised to refine patient selection, enrich clinical trial populations, and enable longitudinal disease monitoring at scale — addressing a longstanding gap in biopsy-dependent assessment.

• Personalized, mechanism-aligned care framework: A pragmatic treatment paradigm is emerging that integrates lifestyle intervention, incretin-based therapies, and liver-directed agents, with the dual goal of mitigating progression to liver-related complications while addressing the excess cardiometabolic morbidity and mortality inherent to this multisystem disorder.

• Semaglutide's expanding evidence base: Semaglutide 2.4 mg has demonstrated combined metabolic and hepatic benefits in obese MASH patients — improving both fibrosis and body weight — and has been identified as a cost-effective option for this population, potentially reducing the long-term clinical and economic burden of MASLD.

• Broader economic and systemic burden: Beyond individual patient management, the growing epidemiological impact of MASLD and its complications represents a substantial economic burden for healthcare systems worldwide, reinforcing the urgency of both pharmacological innovation and integrated care models — including lifestyle modification as a foundational first step — to achieve adequate disease control.